CN1853619B - 阿戈美拉汀在获得用于治疗双相性精神障碍的药物中的用途 - Google Patents

阿戈美拉汀在获得用于治疗双相性精神障碍的药物中的用途 Download PDF

Info

Publication number
CN1853619B
CN1853619B CN2006100764985A CN200610076498A CN1853619B CN 1853619 B CN1853619 B CN 1853619B CN 2006100764985 A CN2006100764985 A CN 2006100764985A CN 200610076498 A CN200610076498 A CN 200610076498A CN 1853619 B CN1853619 B CN 1853619B
Authority
CN
China
Prior art keywords
bipolar disorder
treatment
agomelatine
type
bipolar disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006100764985A
Other languages
English (en)
Other versions
CN1853619A (zh
Inventor
C·德博迪纳
E·莫塞尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35311309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1853619(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Publication of CN1853619A publication Critical patent/CN1853619A/zh
Application granted granted Critical
Publication of CN1853619B publication Critical patent/CN1853619B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

本发明涉及阿戈美拉汀或N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺独自或组合在获得药物中的用途，所述的药物用于治疗双相性精神障碍、特别是I型和II型双相性精神障碍、更特别是I型双相性精神障碍。

Description

阿戈美拉汀在获得用于治疗双相性精神障碍的药物中的用途
技术领域
本发明涉及阿戈美拉汀(agomelatine)或式(I)的N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺以及其水合物、晶形和与可药用酸或碱的加成盐独自或组合在获得药物中的用途，
所述的药物用于治疗双相性精神障碍、特别是I型和II型双相性精神障碍、更特别是I型双相性精神障碍。
背景技术
阿戈美拉汀，或N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺，拥有双重的特性，一方面它是褪黑激素能系统受体的激动剂，另一方面，它又是5-HT2C受体的拮抗剂。这些性质使得它在中枢神经系统中有活性，更特别是在治疗重症抑郁、季节性情感障碍、睡眠障碍、心血管疾病、消化系统疾病、时差导致的失眠和疲惫、食欲障碍和肥胖中有活性。
阿戈美拉汀、其制备及在治疗上的用途已经公开在欧洲专利说明书EP0 447 285和EP 1 564 202中。
发明内容
申请人现已发现，阿戈美拉汀或N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺以及它的水合物、晶形和与可药用酸或碱的加成盐独自或组合使用具有有价值的性质，这使得它们可用于治疗双相性精神障碍，特别是I型和II型双相性精神障碍，更特别是I型双相性精神障碍。
双相性精神障碍是一种对患者的生活有严重影响的精神病理性病症，这种影响既表现在社会和家庭上也表现在职业上。其特征在于通常反复出现抑郁、躁狂、轻度躁狂或混合性发作，这些发作间隔着一段患者未受重症心理功能障碍影响的时期。换句话来说，双相性精神障碍患者以对情绪反复出现显著波动的易感性为特征。发作的特性和它们随时间的发展使得区别出几种临床形式：I型双相性精神障碍是最典型的，其特征是一次或多次躁狂或混合性发作，通常伴随有重症抑郁发作；对II型双相性精神障碍而言，它包括至少一次重症抑郁发作和轻度躁狂发作(躁狂的一种缓和形式)的组合。双相性精神障碍患者的自杀风险很高，25％至50％的患者至少有一次自杀企图。
目前尚没有满意的、公认的双相性精神障碍治疗方法。一线治疗通常是情绪稳定剂或情感调节剂(thymoregulators)，但这些治疗通常不能减轻抑郁症状(J.Clin.Psychiatry，2004，65(4)，569-579)。虽然通常采用同服抗抑郁药，但这是一种引起激烈争论的行为，因为抗抑郁药可引发或加剧躁狂状态和混合状态，当躁狂发作出现时必须停药。抗抑郁药特别被认为可导致或加速情感增盛周期，并两至三倍地促进躁狂或轻度躁狂过程的出现，最后，它们的长期使用似乎可增加抑郁和躁狂发作的次数。
申请人现已令人惊奇地发现，阿戈美拉汀独自或组合可用于治疗双相性精神障碍，特别是I型和II型双相性精神障碍，更特别是I型双相性精神障碍。
正是由于其在抑郁中有活性这一事实，使用阿戈美拉汀治疗双相性精神障碍、更特别是I型双相性精神障碍的预期效果与文献中报道的抗抑郁药如帕罗西汀的效果相同。
令人惊奇地的是，阿戈美拉汀的行为不象常规的抗抑郁药，这一点已从在I型双相性精神障碍患者中进行的临床研究中观察到。这些结果使得考虑其在双相性精神障碍、特别是I型和II型双相性精神障碍、更特别是在I型双相性精神障碍中的使用、甚至是长期使用成为可能。
因此，本发明涉及阿戈美拉汀以及其水合物、晶形和与可药用酸或碱的加成盐独自或组合在获得药物组合物中的用途，所述的药物组合物用于治疗双相性精神障碍，特别是I型和II型双相性精神障碍，更特别是I型双相性精神障碍。
本发明还涉及阿戈美拉汀与情绪稳定剂或情感调节剂的组合，用于获得可用于治疗双相性精神障碍、特别是I型和II型双相性精神障碍、更特别是I型双相性精神障碍的药物组合物。本发明的情绪稳定剂或情感调节剂涉及锂和抗癫痫药如卡马西平、丙戊酸类和拉莫三嗪等等。更特别地，本发明的组合的情绪稳定剂或情感调节剂为锂或丙戊酸类。当阿戈美拉汀与情绪稳定剂组合时，可以在情绪稳定剂之前、同时或之后施用，条件是两次给药之间的时间间隔可使得在中枢神经系统获得预期的协同作用。如果本发明的组合的两种组分同时给药，则优选给予包含阿戈美拉汀和情绪稳定剂以及一种或多种可药用赋形剂的药物组合物。
药物组合物以适宜于通过口服、胃肠道外、经皮、鼻腔、直肠或含化途径给药的形式存在，特别是以注射剂、片剂、舌下片、glossettes、明胶胶囊、胶囊、锭剂、栓剂、乳膏、软膏、皮肤用凝胶等等的形式存在。
除了阿戈美拉汀和任选与之组合的情绪稳定剂外，本发明的药物组合物还包含一种或多种选自稀释剂、润滑剂、粘合剂、崩解剂、吸收剂、着色剂、甜味剂等的赋形剂或载体。
通过非限制实例，可能提到的有：
◆稀释剂：乳糖、葡萄糖、蔗糖、甘露醇、山梨醇、纤维素、甘油；
◆润滑剂：二氧化硅、滑石粉、硬脂酸及其镁盐和钙盐、聚乙二醇；
◆粘合剂：硅酸铝和硅酸镁、淀粉、明胶、西黄蓍胶、甲基纤维素、羧甲基纤维素钠和聚乙烯吡咯烷酮；
◆崩解剂：琼脂、藻酸及其钠盐、泡腾混合物。
有用剂量根据患者的性别、年龄和体重、给药途径、疾病的性质和任何伴随的治疗而不同，阿戈美拉汀的有用剂量为1mg至50mg/24小时。
阿戈美拉汀的日剂量优选为25mg/天。
具体实施方式
药物组合物：
每片含有25mg活性成分的1000片制剂的处方：
N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺    25g
乳糖一水合物                         62g
硬脂酸镁                             1.3g
聚维酮                               9g
无水胶体二氧化硅                     0.3g
纤维素羟乙酸钠                       30g
硬脂酸                               2.6g
临床研究：
本研究在21名患有I型双相性精神障碍的患者中进行，用锂(n＝14)或丙戊酸(n＝7)治疗至少6个月。周阿戈美拉汀(25毫克/天)治疗6周。在这些患者中，19名患者在6周急性治疗后继续治疗，这些继续治疗的患者中有11名治疗达1年。获得的结果表明：81％的患者对治疗有阳性反应，约50％的患者在仅一周治疗的末期有阳性反应。在6周治疗后只观察到3次躁狂或轻度躁狂发作，其水平完全相当于用情绪稳定剂治疗的患者，该结果清楚地表明，阿戈美拉汀在I型双相性精神障碍患者中的阳性作用不伴随有躁狂和/或轻度躁狂发作的发生率提高，甚至在长期治疗后亦如此。

Claims (3)

1.组合产品，包含N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺或其与可药用酸或碱的加成盐以及情感调节剂，其中所述的情感调节剂是锂或丙戊酸。
2.药物组合物，该组合物仅包含权利要求1所述的组合产品，或者还包含一种或多种可药用赋形剂。
3.权利要求1所述的组合产品在获得药物组合物中的用途，所述的药物组合物用于治疗I型双相性精神障碍。
CN2006100764985A 2005-04-20 2006-04-20 阿戈美拉汀在获得用于治疗双相性精神障碍的药物中的用途 Expired - Fee Related CN1853619B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0503937A FR2884714B1 (fr) 2005-04-20 2005-04-20 Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires
FR0503937 2005-04-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2010105781057A Division CN102038669A (zh) 2005-04-20 2006-04-20 阿戈美拉汀在获得用于治疗双相性精神障碍的药物中的用途

Publications (2)

Publication Number Publication Date
CN1853619A CN1853619A (zh) 2006-11-01
CN1853619B true CN1853619B (zh) 2011-02-02

Family

ID=35311309

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2006100764985A Expired - Fee Related CN1853619B (zh) 2005-04-20 2006-04-20 阿戈美拉汀在获得用于治疗双相性精神障碍的药物中的用途
CN2010105781057A Pending CN102038669A (zh) 2005-04-20 2006-04-20 阿戈美拉汀在获得用于治疗双相性精神障碍的药物中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010105781057A Pending CN102038669A (zh) 2005-04-20 2006-04-20 阿戈美拉汀在获得用于治疗双相性精神障碍的药物中的用途

Country Status (41)

Country Link
US (1) US7947743B2 (zh)
EP (1) EP1714647B1 (zh)
JP (2) JP4580364B2 (zh)
KR (2) KR100835451B1 (zh)
CN (2) CN1853619B (zh)
AP (1) AP2656A (zh)
AR (1) AR057277A1 (zh)
AT (1) ATE491443T1 (zh)
AU (1) AU2006201655B2 (zh)
BR (1) BRPI0601285A8 (zh)
CA (1) CA2544136C (zh)
CR (1) CR9426A (zh)
CY (1) CY1111257T1 (zh)
DE (1) DE602006018822D1 (zh)
DK (1) DK1714647T3 (zh)
EA (1) EA013462B1 (zh)
ES (1) ES2357901T3 (zh)
FR (1) FR2884714B1 (zh)
GE (1) GEP20094651B (zh)
GT (1) GT200600141A (zh)
HK (1) HK1093906A1 (zh)
HR (1) HRP20110083T1 (zh)
IL (1) IL186373A (zh)
JO (1) JO2666B1 (zh)
MA (1) MA28266A1 (zh)
ME (1) ME01951B (zh)
MY (1) MY143171A (zh)
NO (1) NO336010B1 (zh)
NZ (1) NZ546630A (zh)
PE (1) PE20061337A1 (zh)
PL (1) PL1714647T3 (zh)
PT (1) PT1714647E (zh)
RS (1) RS51659B (zh)
SG (1) SG126868A1 (zh)
SI (1) SI1714647T1 (zh)
TN (1) TNSN07364A1 (zh)
TW (2) TW200940049A (zh)
UA (1) UA83681C2 (zh)
UY (1) UY29470A1 (zh)
WO (1) WO2006111653A1 (zh)
ZA (1) ZA200603160B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2890563B1 (fr) * 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un agent thymoregulateur et les compositions pharmaceutiques qui la contiennent
EP2150525A1 (en) 2007-05-01 2010-02-10 Concert Pharmaceuticals Inc. Naphthyl(ethyl) acetamides
FR2978916B1 (fr) * 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
EP2856934A1 (en) * 2013-10-04 2015-04-08 Les Laboratoires Servier Biomarkers for the prediction of long term remission in depression

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225442A (en) * 1990-02-27 1993-07-06 Adir Et Compagnie Compounds having a naphthalene structure

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585118A (en) * 1995-06-02 1996-12-17 Brigham And Women's Hospital Choline in the treatment of bipolar disorder
WO2002067924A1 (en) * 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating bipolar disorder
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
AU2004308962A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225442A (en) * 1990-02-27 1993-07-06 Adir Et Compagnie Compounds having a naphthalene structure

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
David A. K. 等.Treatment of bipolar disorder: a guide for patients and families.Treatment of bipolar disorder.2004,109-116.
David A. K.等.Treatment of bipolar disorder: a guide for patients and families.Treatment of bipolar disorder.2004,109-116. *
H. loo等.Determination of the dose of agomelatine , amelatoninergic agonist and selective 5-HT2c antagonist, inthe treatment of major depressive disorder: a placebo-controlled dose range study.International clinical psychopharmacology17.2002,17239-247.
H. loo等.Determination of the dose of agomelatine, amelatoninergic agonist and selective 5-HT2c antagonist, inthe treatment of major depressive disorder: a placebo-controlled dose range study.International clinical psychopharmacology17.2002,17239-247. *
沈其杰.双相情感障碍药物治疗规范化程序草案.临床精神医学杂志12 1.2002,12(1),51-53.
沈其杰.双相情感障碍药物治疗规范化程序草案.临床精神医学杂志12 1.2002,12(1),51-53. *
陈国俊综述.丙戊酸抗癫痫机制.临床精神病学杂志6 2.1993,6(2),124-125.
陈国俊综述.丙戊酸抗癫痫机制.临床精神病学杂志6 2.1993,6(2),124-125. *

Also Published As

Publication number Publication date
PT1714647E (pt) 2011-01-14
IL186373A (en) 2012-06-28
GT200600141A (es) 2006-11-22
AU2006201655B2 (en) 2009-04-23
GEP20094651B (en) 2009-03-25
HRP20110083T1 (hr) 2011-03-31
TW200716083A (en) 2007-05-01
KR20060110803A (ko) 2006-10-25
AR057277A1 (es) 2007-11-28
ATE491443T1 (de) 2011-01-15
ES2357901T3 (es) 2011-05-03
US7947743B2 (en) 2011-05-24
SG126868A1 (en) 2006-11-29
ME01951B (me) 2011-10-31
EA013462B1 (ru) 2010-04-30
JP2006316056A (ja) 2006-11-24
KR20080028389A (ko) 2008-03-31
TWI318115B (en) 2009-12-11
JP5341037B2 (ja) 2013-11-13
CY1111257T1 (el) 2015-08-05
AU2006201655A1 (en) 2006-11-09
NO336010B1 (no) 2015-04-20
JP2010280699A (ja) 2010-12-16
MA28266A1 (fr) 2006-11-01
BRPI0601285A (pt) 2006-12-19
PE20061337A1 (es) 2007-01-27
SI1714647T1 (sl) 2011-03-31
JO2666B1 (en) 2012-06-17
US20060240127A1 (en) 2006-10-26
IL186373A0 (en) 2008-08-07
EA200600600A1 (ru) 2006-10-27
AP2656A (en) 2013-05-07
EP1714647B1 (fr) 2010-12-15
HK1093906A1 (en) 2007-03-16
UA83681C2 (uk) 2008-08-11
CN102038669A (zh) 2011-05-04
CN1853619A (zh) 2006-11-01
CR9426A (es) 2008-02-21
RS51659B (en) 2011-10-31
ZA200603160B (en) 2007-06-27
KR100835451B1 (ko) 2008-06-09
FR2884714A1 (fr) 2006-10-27
PL1714647T3 (pl) 2011-05-31
NO20061705L (no) 2006-10-23
UY29470A1 (es) 2006-05-31
MY143171A (en) 2011-03-31
WO2006111653A1 (fr) 2006-10-26
NZ546630A (en) 2007-09-28
TW200940049A (en) 2009-10-01
DE602006018822D1 (de) 2011-01-27
JP4580364B2 (ja) 2010-11-10
FR2884714B1 (fr) 2011-05-06
CA2544136A1 (fr) 2006-10-20
TNSN07364A1 (en) 2008-12-31
BRPI0601285A8 (pt) 2021-03-30
DK1714647T3 (da) 2011-03-07
AP2007004212A0 (en) 2007-10-31
CA2544136C (fr) 2012-02-21
EP1714647A1 (fr) 2006-10-25

Similar Documents

Publication Publication Date Title
CN101049290B (zh) 阿戈美拉汀在制备用于治疗广泛性焦虑症的药物中的用途
CN1927193B (zh) 阿戈美拉汀在获得用于治疗抑郁患者睡眠障碍的药物中的用途
US20070123571A1 (en) Use of a compound in the treatment of sleep disorders
TW200412934A (en) Pharmaceutical formulations of modafinil
BRPI0618239A2 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusico
TWI694069B (zh) 治療精神分裂症之醫藥調配物
RU2007123565A (ru) Композиции разагилина, распадающиеся в ротовой полости
JP3929618B2 (ja) 口中溶解型又は咀嚼型鼻炎治療用固形内服医薬組成物
AU2010211491A1 (en) Medical use of 5-benzylaminosalicylic acid derivative or its salt
WO2023237124A1 (zh) 一种藏红花素混悬剂及其在制备快速抗抑郁药物中的应用
CN1853619B (zh) 阿戈美拉汀在获得用于治疗双相性精神障碍的药物中的用途
JP2004525940A (ja) 火照りの処置のためのデュロキセチン
ES2390225T3 (es) Combinación del analéptico modafinilo y de un antidepresivo para el tratamiento de la depresión
RU2004119832A (ru) Применение соединения для лечения нарушений сна и т.п. для обеспечения состояния бодрости после пробуждения и способ лечения состояния разбитости
WO1998024411A2 (en) Method for oral administration of buspirone
CN101194901A (zh) 阿戈美拉汀在制备用于治疗Smith-Magenis综合征的药物中的用途
US11364261B2 (en) Alleviating common cold and influenza symptoms with molecular hydrogen
ES2314440T3 (es) Composicion farmaceutica bucodispersable de un compuesto antitrombotico.
KR20010105418A (ko) 기분 장애 치료용 오사네턴트
JP4384435B2 (ja) くしゃみ抑制組成物
CN109069450A (zh) 神经障碍的新的组合疗法
CN112691102A (zh) 黄芩素在防治帕金森病/帕金森综合征抑郁症状中的应用
EP3854391B1 (en) Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
EP0626849A1 (en) Brofaromine as an agent for treating post-traumatic stress
RU2002115814A (ru) Лечение системной красной волчанки с помощью дегидроэпиандростерона

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1093906

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1093906

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110202

Termination date: 20200420

CF01 Termination of patent right due to non-payment of annual fee